

KAZIA
THERAPEUTICS



2023 Annual General Meeting R&D and Clinical Overview

John Friend, MD
Chief Executive Officer

30 November 2023

Forward-Looking Statements

This presentation contains **forward-looking statements** within the meaning of the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve substantial risks and uncertainties, not all of which may be known at the time. All statements contained in this presentation, other than statements of historical fact, including statements regarding our strategy, research and development plans, collaborations, future operations, future financial position, future revenues, projected costs, prospects, plans, and objectives of management, are forward-looking statements. Not all forward-looking statements in this presentation are explicitly identified as such.

Many factors could cause the actual results of the Company to differ materially from the results expressed or implied herein, and you should not place undue reliance on the forward-looking statements. Factors which could change the Company's expected outcomes include, without limitation, our ability to: advance the development of our programs, and to do so within any timelines that may be indicated herein; the safety and efficacy of our drug development candidates; our ability to replicate experimental data; the ongoing validity of patents covering our drug development candidates, and our freedom to operate under third party intellectual property; our ability to obtain necessary regulatory approvals; our ability to enter into and maintain partnerships, collaborations, and other business relationships necessary to the progression of our drug development candidates; the timely availability of necessary capital to pursue our business objectives; and our ability to attract and retain qualified personnel; changes from anticipated levels of customer acceptance of existing and new products and services and other factors.

Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can therefore be no assurance that such expectations will prove to be correct. The Company has no obligation as a result of this presentation to clinical trial outcomes, sales, partnerships, future international, national or regional economic and competitive conditions, changes in relationships with customers, access to capital, difficulties in developing and marketing new products and services, or marketing existing products.

In addition, the extent to which the COVID-19 outbreak continues to impact our workforce and our discovery research, supply chain and clinical trial operations activities, and the operations of the third parties on which we rely, will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration and severity of the outbreak, additional or modified government actions, and the actions that may be required to contain the virus or treat its impact.

Any forward-looking statements contained in this presentation speak only as of the date this presentation is made, and we expressly disclaim any obligation to update any forward-looking statements, whether because of new information, future events or otherwise.

Kazia R&D and clinical advancements during 2023 has been steady and positive

Paxalisib

Institution	Disease/Study	Key Developments	Month
ANZCHOG	Molecular-driven childhood & adolescent cancer	Clinical Trial (OPTIMISE) collaboration	March
AACR	Melanoma, DMG/DIPG & AT/RT	Preclinical data presented	April
SNO Peds	DMG/DIPG & AT/RT	Preclinical data presented	June
COGNO	PI3K targeted Low Grade Glioma	Clinical Trial (LUMOS2) collaboration	June
FDA	Treatment of solid tumor brain metastases harboring PI3K pathway mutations in combination with radiation therapy	Fast Track Designation granted	July
SMR	Melanoma	Preclinical data presented	November
SNO	Combination with ONC201 in DMG	Preclinical data presented	November
SNO	PNOC022 in DMG	Clinical data presented (late-breaking abstract)	November
SNO	Combination with PKC Inhibitor in DMG	Preclinical data presented	November
SNO	Combination with radiation therapy	Interim phase I/II data presented	November

EVT801

Institution	Disease/Study	Key Developments	Month
AACR	KZA 0801 101 – Phase 1 Study	Clinical and Biomarker abstracts and posters presented	April
ESMO	KZA 0801 101 – Phase 1 Study	Clinical and Biomarker abstracts and posters presented	October

Paxalisib clinical study status - Pediatric Brain Cancer Pillar

Pediatric Brain Cancer Studies		
Protocol Number	Study Name	Study Update
PNOC022	Study Name: A Combination Therapy Trial using an Adaptive Platform Design for Children and Young Adults with Diffuse Midline Gliomas (DMGs) including Diffuse Intrinsic Pontine Gliomas (DIPGs) at Initial Diagnosis, Post-Radiation Therapy and at Time of Progression	<p>Study Start Date: October 2021 Total enrolled to date: 138 patients</p> <p>Overall Survival Data from Cohort 2 16.5 months presented at SNO 2023 Enrollment on hold for data review of other 2 cohorts. Protocol amendment is under advisement to optimize efficacy and tolerability</p>
ANZCHOG2204	Optimal Precision Therapies to CustomISE Care in Childhood and Adolescent Cancer (OPTIMISE)	<p>Anticipated Study Start Date: December 2023 Australia-based pediatric cancer centers Considering expansion to Canadian centers PI3K pathway mutation required for enrollment on Paxalisib arm</p>

Paxalisib clinical study status – Adult Primary Brain Cancer

Adult Brain Cancer Studies		
Protocol Number	Study Name	Study Update
GCAR-7213	GBM AGILE Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent Glioblastoma (GBM)	Data in final stages of cleaning and analysis Based on last discussion with the study sponsor (GCAR), Kazia will not receive the data in December
21-05023537	Weill Cornell Medicine - Paxalisib With a High Fat, Low Carb Diet and Metformin for Glioblastoma	Study Start Date: November 2021 Total enrolled to date: 14 patients
21-109	Dana-Farber Cancer Institute - Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL	Study Start Date: March 2021 Total enrolled to date: 14 patients Update re. promising clinical activity and protocol amendment underway
CTC 0378	LUMOS2: Low & Anaplastic Grade Glioma Umbrella Study of MOlecular Guided Therapies. A phase 2, prospective, multi-centre, open-label, multiarm, biomarker-directed, signal-seeking, umbrella clinical trial for recurrent IDH mutant, grade 2/3 glioma.	Study Start Date: September 2023 Total enrolled to date: 1 patient Total enrolment anticipated = 19

Paxalisib clinical study status – Adult Brain Metastases

Adult Brain Metastases Studies		
Protocol Number	Study Name	Study Update
19-359	Memorial Sloan Kettering Cancer Center - GDC-0084 With Radiation Therapy for People With PIK3CA-Mutated Solid Tumor Brain Metastases or Leptomeningeal Metastases	Study Start Date: November 2019 Total enrolled to date: 17 patients Expansion cohort enrolling Anticipate data 1H24
A071701	National Cancer Institute/Alliance for Clinical Trials in Oncology - Genetic Testing in Guiding Treatment for Patients With Brain Metastases	Study Start Date: August 2019 Total enrolled to date: 17 patients
18-516	Dana-Farber Cancer Institute - GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases	Study Start Date: Nov 2018 Total enrolled to date: 14 patients

Paxalisib - Research and Development

QIMR – Professor Sudha Rao

- Key Development
 - Evaluating PI3K inhibition as an immune modulator of the tumor and tumor microenvironment
 - Can paxalisib activate the immune system within the tumor, making it more susceptible to immunotherapy and what is the molecular rationale behind this?
 - In spite of the advances in the treatment of many cancers (ex. Breast and lung), some patients quickly progress or do not respond to immunotherapy
 - In treatment-resistant pre-clinical models of breast cancer, paxalisib has shown encouraging results in inhibiting both the primary tumour burden and metastasis by reinvigorating the immune system within the tumour microenvironment.
 - We expect to share preliminary results of the research next month (December 2023) and discussing potential next steps

University Utah – Professor Sheri Holman


- Key Development
 - PI3K-AKT-mTOR pathway alterations are critical component of primary and secondary therapeutic resistance in metastatic melanoma
 - Paxalisib monotherapy as well in combination w/BRAF demonstrated significant survival benefit
- AACR 2023 data presented an Overall Survival benefit of Paxalisib over standard BRAF+MEK in highly resistant melanoma mouse model
- This research led to an online publication in **Molecular Cancer Therapeutics** in November 2023
- The authors concluded: "Our results support the use of paxalisib as a single agent either in the first line or MAPK inhibitor resistant setting for BRAF-mutant cutaneous melanoma. In this paper, we demonstrate the beneficial use of next generation PI3K/mTOR inhibitors, notably paxalisib, to inhibit melanoma cell growth."

EVT801 - Phase 1 clinical study continues to enroll as planned

EVT801 Clinical Study		
Protocol Number	Study Name	Study Update
KZA 0801-101	A Phase 1, First in Human, Open Label Study to Assess the Safety, Tolerability, and Pharmacokinetics of EVT801 in Patients with Advanced Solid Tumours	<p>To date 28 patients included in the study</p> <ul style="list-style-type: none">• 22 patients treated• 5 dosing cohorts completed up to 400mg BID• Actively enrolling patients in the 500mg BID cohort <p>Number of patients have remained on treatment for two or more cycles with one reaching Cycle 9</p> <p>Biomarkers have shown strong VEGFR3 expression, and we have observed encouraging clinical activity in HGS ovarian cancer patients</p>

Looking to 2024 and beyond...

- Engaging new investors
 - Short term (6-month) Promissory note USD \$500,000 from new European investor
- Continue discussions and engagement with leading US investment banks
- Explore strategic and alternative opportunities for paxalisib and EVT-801
- Opportunistic use of ATM
- Continued execution in 2024 of the R&D and clinical pipeline, including:
 - Data from QIMR collaboration in solid tumors
 - PNOC022 two additional cohorts of data
 - Expansion stage of MSKCC Paxalisib + Radiation Therapy clinical study
 - GBM Agile phase 3 data



KAZIA
THERAPEUTICS

www.kaziatherapeutics.com

info@kaziatherapeutics.com